Self-reported sexual function in depressed patients and serotonin 4 receptor brain binding: A Positron Emission Tomography study

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningfagfællebedømt

Standard

Self-reported sexual function in depressed patients and serotonin 4 receptor brain binding : A Positron Emission Tomography study. / Rasmussen, A. Laebo; Larsen, S. Vinther; Stenbaek, D. Siggaard; Jorgensen, M. Balslev; Giraldi, A.; Frokjaer, V. G.

I: European Neuropsychopharmacology, Bind 53, Nr. S1, 2021, s. S290-S291.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningfagfællebedømt

Harvard

Rasmussen, AL, Larsen, SV, Stenbaek, DS, Jorgensen, MB, Giraldi, A & Frokjaer, VG 2021, 'Self-reported sexual function in depressed patients and serotonin 4 receptor brain binding: A Positron Emission Tomography study', European Neuropsychopharmacology, bind 53, nr. S1, s. S290-S291. https://doi.org/10.1016/j.euroneuro.2021.10.375

APA

Rasmussen, A. L., Larsen, S. V., Stenbaek, D. S., Jorgensen, M. B., Giraldi, A., & Frokjaer, V. G. (2021). Self-reported sexual function in depressed patients and serotonin 4 receptor brain binding: A Positron Emission Tomography study. European Neuropsychopharmacology, 53(S1), S290-S291. https://doi.org/10.1016/j.euroneuro.2021.10.375

Vancouver

Rasmussen AL, Larsen SV, Stenbaek DS, Jorgensen MB, Giraldi A, Frokjaer VG. Self-reported sexual function in depressed patients and serotonin 4 receptor brain binding: A Positron Emission Tomography study. European Neuropsychopharmacology. 2021;53(S1):S290-S291. https://doi.org/10.1016/j.euroneuro.2021.10.375

Author

Rasmussen, A. Laebo ; Larsen, S. Vinther ; Stenbaek, D. Siggaard ; Jorgensen, M. Balslev ; Giraldi, A. ; Frokjaer, V. G. / Self-reported sexual function in depressed patients and serotonin 4 receptor brain binding : A Positron Emission Tomography study. I: European Neuropsychopharmacology. 2021 ; Bind 53, Nr. S1. s. S290-S291.

Bibtex

@article{0a02018166204475935b89d3c540d3ef,
title = "Self-reported sexual function in depressed patients and serotonin 4 receptor brain binding: A Positron Emission Tomography study",
abstract = "Background: Sexual dysfunction is a prominent feature of Major Depressive Disorder (MDD) reaching a prevalence as high as 75% and is more pronounced in women than in men with MDD [1]. Anhedonia, a core symptom in MDD, may also be reflected in reduced sexual desire and/or interest and may be related to disturbed reward processing. The serotonin 4 receptor (5-HT4R) is richly expressed in the striatum, a key hub in the reward circuitry, and appears to be associated with functional MRI measures of reward related brain activity in healthy individuals, as shown by our group [2]. Thus, disturbances in reward circuit brain function, possibly related to serotonin brain signalling, may play a role in anhedonia.Aim: To determine if serotonergic function, in terms of striatal 5-HT4R non-displaceable binding (BPND), is associated with self-reported sexual function in the untreated depressed state and whether this depends on gender. We further evaluate if sexual health measures align with overall anhedonia psychometrics.Methods: Data on [11C]-SB207145 PET imaging and sexual health were available from the Center for Integrated Molecular Brain Imaging (Cimbi) database [3] from 86 untreated MDD patients (male/female = 25/61) [4]. Sexual function was evaluated using the Changes in Sexual Functioning Questionnaire (CSFQ-14) for men and women respectively and was defined in a binary fashion as either being in risk of having a sexual dysfunction or not based on validated cut-off points from the CSFQ-14 total score [5]. The Snaith-Hamilton Pleasure Scale (SHAPS) was used to assess perceived level of anhedonia.We evaluated the association between striatal 5-HT4R BPND and sexual function as a dichotomized variable using multiple linear regression models adjusting for relevant covariates (i.e. age, sex, the serotonin transporter polymorphism (5-HTTLPR) genotype (LALA or non-LALA) and injected [11C]-SB207145 mass per kg bodyweight). Further, we tested if this association was dependent on gender. Finally, we evaluated the association between the total scores of the SHAPS- and the CSFQ-14 questionnaires in a linear regression model for men and women separately since the CSFQ scale differs with sex.Results: Eight men (14.8%) and 46 women (85.2%) met the threshold indicating a sexual dysfunction. We found no significant association between striatal 5-HT4R BPND and sexual function (0.05, CI [-0.4: 0.5], p=0.8). Likewise, such association did not differ between men and women (-0.3, CI [-0.8: 0.2], p=0.3). As expected, the total scores of the SHAPS questionnaires were negatively associated with the CSFQ-14 total scores women (-0.15, CI [-0.26: -0.05], p=0.005), whereas we were underpowered to conclude on such an association in men (-0.06, CI [-0.22: 0.09], p=0.41).Conclusion: Overall our data suggest that sexual (dys)function in depression, for both men and women, does not map onto a marker of serotonergic wiring of the reward system, in terms of 5-HT4R BPND. Nevertheless, our data suggest that in the depressed state sexual dysfunction may serve as a proxy for anhedonia at least in women.",
author = "Rasmussen, {A. Laebo} and Larsen, {S. Vinther} and Stenbaek, {D. Siggaard} and Jorgensen, {M. Balslev} and A. Giraldi and Frokjaer, {V. G.}",
year = "2021",
doi = "10.1016/j.euroneuro.2021.10.375",
language = "English",
volume = "53",
pages = "S290--S291",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "S1",

}

RIS

TY - ABST

T1 - Self-reported sexual function in depressed patients and serotonin 4 receptor brain binding

T2 - A Positron Emission Tomography study

AU - Rasmussen, A. Laebo

AU - Larsen, S. Vinther

AU - Stenbaek, D. Siggaard

AU - Jorgensen, M. Balslev

AU - Giraldi, A.

AU - Frokjaer, V. G.

PY - 2021

Y1 - 2021

N2 - Background: Sexual dysfunction is a prominent feature of Major Depressive Disorder (MDD) reaching a prevalence as high as 75% and is more pronounced in women than in men with MDD [1]. Anhedonia, a core symptom in MDD, may also be reflected in reduced sexual desire and/or interest and may be related to disturbed reward processing. The serotonin 4 receptor (5-HT4R) is richly expressed in the striatum, a key hub in the reward circuitry, and appears to be associated with functional MRI measures of reward related brain activity in healthy individuals, as shown by our group [2]. Thus, disturbances in reward circuit brain function, possibly related to serotonin brain signalling, may play a role in anhedonia.Aim: To determine if serotonergic function, in terms of striatal 5-HT4R non-displaceable binding (BPND), is associated with self-reported sexual function in the untreated depressed state and whether this depends on gender. We further evaluate if sexual health measures align with overall anhedonia psychometrics.Methods: Data on [11C]-SB207145 PET imaging and sexual health were available from the Center for Integrated Molecular Brain Imaging (Cimbi) database [3] from 86 untreated MDD patients (male/female = 25/61) [4]. Sexual function was evaluated using the Changes in Sexual Functioning Questionnaire (CSFQ-14) for men and women respectively and was defined in a binary fashion as either being in risk of having a sexual dysfunction or not based on validated cut-off points from the CSFQ-14 total score [5]. The Snaith-Hamilton Pleasure Scale (SHAPS) was used to assess perceived level of anhedonia.We evaluated the association between striatal 5-HT4R BPND and sexual function as a dichotomized variable using multiple linear regression models adjusting for relevant covariates (i.e. age, sex, the serotonin transporter polymorphism (5-HTTLPR) genotype (LALA or non-LALA) and injected [11C]-SB207145 mass per kg bodyweight). Further, we tested if this association was dependent on gender. Finally, we evaluated the association between the total scores of the SHAPS- and the CSFQ-14 questionnaires in a linear regression model for men and women separately since the CSFQ scale differs with sex.Results: Eight men (14.8%) and 46 women (85.2%) met the threshold indicating a sexual dysfunction. We found no significant association between striatal 5-HT4R BPND and sexual function (0.05, CI [-0.4: 0.5], p=0.8). Likewise, such association did not differ between men and women (-0.3, CI [-0.8: 0.2], p=0.3). As expected, the total scores of the SHAPS questionnaires were negatively associated with the CSFQ-14 total scores women (-0.15, CI [-0.26: -0.05], p=0.005), whereas we were underpowered to conclude on such an association in men (-0.06, CI [-0.22: 0.09], p=0.41).Conclusion: Overall our data suggest that sexual (dys)function in depression, for both men and women, does not map onto a marker of serotonergic wiring of the reward system, in terms of 5-HT4R BPND. Nevertheless, our data suggest that in the depressed state sexual dysfunction may serve as a proxy for anhedonia at least in women.

AB - Background: Sexual dysfunction is a prominent feature of Major Depressive Disorder (MDD) reaching a prevalence as high as 75% and is more pronounced in women than in men with MDD [1]. Anhedonia, a core symptom in MDD, may also be reflected in reduced sexual desire and/or interest and may be related to disturbed reward processing. The serotonin 4 receptor (5-HT4R) is richly expressed in the striatum, a key hub in the reward circuitry, and appears to be associated with functional MRI measures of reward related brain activity in healthy individuals, as shown by our group [2]. Thus, disturbances in reward circuit brain function, possibly related to serotonin brain signalling, may play a role in anhedonia.Aim: To determine if serotonergic function, in terms of striatal 5-HT4R non-displaceable binding (BPND), is associated with self-reported sexual function in the untreated depressed state and whether this depends on gender. We further evaluate if sexual health measures align with overall anhedonia psychometrics.Methods: Data on [11C]-SB207145 PET imaging and sexual health were available from the Center for Integrated Molecular Brain Imaging (Cimbi) database [3] from 86 untreated MDD patients (male/female = 25/61) [4]. Sexual function was evaluated using the Changes in Sexual Functioning Questionnaire (CSFQ-14) for men and women respectively and was defined in a binary fashion as either being in risk of having a sexual dysfunction or not based on validated cut-off points from the CSFQ-14 total score [5]. The Snaith-Hamilton Pleasure Scale (SHAPS) was used to assess perceived level of anhedonia.We evaluated the association between striatal 5-HT4R BPND and sexual function as a dichotomized variable using multiple linear regression models adjusting for relevant covariates (i.e. age, sex, the serotonin transporter polymorphism (5-HTTLPR) genotype (LALA or non-LALA) and injected [11C]-SB207145 mass per kg bodyweight). Further, we tested if this association was dependent on gender. Finally, we evaluated the association between the total scores of the SHAPS- and the CSFQ-14 questionnaires in a linear regression model for men and women separately since the CSFQ scale differs with sex.Results: Eight men (14.8%) and 46 women (85.2%) met the threshold indicating a sexual dysfunction. We found no significant association between striatal 5-HT4R BPND and sexual function (0.05, CI [-0.4: 0.5], p=0.8). Likewise, such association did not differ between men and women (-0.3, CI [-0.8: 0.2], p=0.3). As expected, the total scores of the SHAPS questionnaires were negatively associated with the CSFQ-14 total scores women (-0.15, CI [-0.26: -0.05], p=0.005), whereas we were underpowered to conclude on such an association in men (-0.06, CI [-0.22: 0.09], p=0.41).Conclusion: Overall our data suggest that sexual (dys)function in depression, for both men and women, does not map onto a marker of serotonergic wiring of the reward system, in terms of 5-HT4R BPND. Nevertheless, our data suggest that in the depressed state sexual dysfunction may serve as a proxy for anhedonia at least in women.

U2 - 10.1016/j.euroneuro.2021.10.375

DO - 10.1016/j.euroneuro.2021.10.375

M3 - Conference abstract in journal

VL - 53

SP - S290-S291

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - S1

ER -

ID: 302543913